Brought to you by 
Galantos Pharma secures €4.4mm in Series C round
06 May 2010
Executive Summary
Galantos Pharma GMBH (neuroprotective drug candidates) has brought in €4.4mm ($5.7mm) through a Series C financing, which will help advance the company's lead candidate Memogain (galantamine prodrug) into human testing for Alzheimer's disease. Existing shareholders Investment Bank Rhineland Palatinate (FIB) and High-Tech Gruenderfonds (HTGF) were joined by Rhineland Palatinate Fund (VRP), Venture Fund Rhineland Palatinate (WFT), and the German State Bank (KfW). The German Ministry for Education and Research (BMBF) also provided grant funding. The Series C money should last Galantos through the end of next year, when it plans to partner Memogain.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Galantos Pharma secures €4.4mm in Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice